Swedish private-equity firm EQT said that together with its co-shareholders it has agreed to sell Ellab to Novo Holdings.
Headquartered in Hillerod, Denmark, Ellab provides validation and monitoring solutions and services for biotech and pharmaceutical processes.
EQT said it invested in the company in 2019 and since then Ellab has tripled its revenue, earnings before interest, tax, depreciation and amortization and number of employees, while experiencing around 20% annual organic revenue growth and completing 15 add-on acquisitions.
Get the week’s top news delivered directly to your inbox – Sign up for our newsletter
The sale to Novo Holdings is expected to close in the third quarter, subject to regulatory approval.
Novo Holdings is a holding and investment company responsible for managing the assets and the wealth of the Novo Nordisk Foundation. Wholly-owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk and Novozymes.
Source: Market Watch
Can’t stop reading? Read more
Blackstone boosts hospitality portfolio with $200m Sunseeker Resort deal
Blackstone boosts hospitality portfolio with $200m Sunseeker Resort deal Blackstone Real Estate...
Apollo appoints Brian Chu to lead operational value creation platform APPS
Apollo appoints Brian Chu to lead operational value creation platform APPS Apollo Global...
TDR Capital eyes £2bn continuation deal for David Lloyd Leisure
TDR Capital eyes £2bn continuation deal for David Lloyd Leisure TDR Capital is nearing a £2bn...